Efficacy and Safety of Coadministered Ezetimibe-Rosuvastatin plus Telmisartan in South Korean Patients with Dyslipidemia and Hypertension: A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase III Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Zhao-Yan | - |
dc.contributor.author | Kim, Moo-Hyun | - |
dc.contributor.author | Lee, Han-Cheol | - |
dc.contributor.author | Park, Sung-Ji | - |
dc.contributor.author | Rhee, Moo-Yong | - |
dc.contributor.author | Choi, Jong-Il | - |
dc.contributor.author | Kim, Sang-Hyun | - |
dc.contributor.author | Chae, In-Ho | - |
dc.contributor.author | Hong, Young-Joon | - |
dc.contributor.author | Lee, Nam-Ho | - |
dc.contributor.author | Hwang, Gyo-Seung | - |
dc.contributor.author | Hur, Seung-Ho | - |
dc.contributor.author | Son, Jung-Woo | - |
dc.contributor.author | Chae, Jei-Keon | - |
dc.contributor.author | Kim, Hyo-Soo | - |
dc.date.accessioned | 2024-11-13T23:03:25Z | - |
dc.date.available | 2024-11-13T23:03:25Z | - |
dc.date.issued | 2023-03-01 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/165002 | - |
dc.description.abstract | Background: The introduction of a fixed-dose combination (FDC) is expected to improve treatment compliance. Methods: There were 181 subjects who were randomized to three groups: ezetimibe-rosuvastatin 10/20 mg + telmisartan 80 mg, ezetimibe-rosuvastatin 10/20 mg, and telmisartan 80 mg. The primary outcomes were change in mean sitting systolic blood pressure (MSSBP) and percentage change in low-density-lipoprotein cholesterol (LDL-C) compared to baseline at week 8. Results: The least-square mean (SE) in MSSBP changes between the ezetimibe-rosuvastatin 10/20 mg + telmisartan 80 mg group and the ezetimibe-rosuvastatin 10/20 mg group were -25.81 (2.34) mmHg and -7.66 (2.45) mmHg. There was a significant difference between the two groups (-18.15 (2.83) mmHg, 95% CI -23.75 to -12.56, p < 0.0001). Changes in least-square mean (SE) in LDL-C between the ezetimibe-rosuvastatin 10/20 mg + telmisartan 80 mg group and the telmisartan 80 mg group were -63.82 (2.87)% and -2.48 (3.12)%. A significant difference was observed between the two groups (-61.34 (3.33)%, 95% CI -67.91 to -54.78, p < 0.0001). No serious adverse events were observed. Conclusions: Ezetimibe-rosuvastatin plus telmisartan treatment is effective and safe when compared to either ezetimibe-rosuvastatin or telmisartan. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI | - |
dc.title | Efficacy and Safety of Coadministered Ezetimibe-Rosuvastatin plus Telmisartan in South Korean Patients with Dyslipidemia and Hypertension: A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase III Trial | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/jcm12062377 | - |
dc.identifier.scopusid | 2-s2.0-85151355841 | - |
dc.identifier.wosid | 000956132500001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL MEDICINE, v.12, no.6 | - |
dc.citation.title | JOURNAL OF CLINICAL MEDICINE | - |
dc.citation.volume | 12 | - |
dc.citation.number | 6 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | DENSITY-LIPOPROTEIN CHOLESTEROL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | ADHERENCE | - |
dc.subject.keywordPlus | STATINS | - |
dc.subject.keywordAuthor | hypertension | - |
dc.subject.keywordAuthor | dyslipidemia | - |
dc.subject.keywordAuthor | ezetimibe | - |
dc.subject.keywordAuthor | rosuvastatin | - |
dc.subject.keywordAuthor | telmisartan | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.